Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2023 | NE3107 properties and mode of action

Joseph Michael Palumbo, MD, BioVie Inc., Carson City, NV, describes NE3107 and its use in degenerative dementia. NE3107 is a small molecule that is orally available and delivered twice a day by mouth. It is a derivative of the human metabolite of DHEA that enters the brain easily. The compound has anti-inflammatory properties by preventing the formation of TNF-alpha by blocking certain inflammatory cytokines and their creation. It is also an insulin sensitizer, which means it has an effect on the brain and periphery. This interview took place at the AAN Annual Meeting 2023 in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Dr Palumbo is a full-time employee of BioVie, Inc.